Skip to main content
SpringerLink
Log in

Authors’ Reply to Alain Braillon’s Comment on “Proactive regional pharmacovigilance system versus national spontaneous reporting for collecting safety data on concerning off-label prescribing practices: An example with baclofen and alcohol dependence in France’’

  • Letter to the Editor
  • Published:
Drug Safety Aims and scope Submit manuscript

The Original Article was published on 10 February 2017

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Braillon A. Comment on: “Proactive regional pharmacovigilance system versus national spontaneous reporting for collecting safety data on concerning off-label prescribing practices: An example with baclofen and alcohol dependence in France”. Drug Saf. 2017. doi:10.1007/s40264-017-0512-7.

  2. Auffret M, Labreuche J, Duhamel A, et al. Proactive regional pharmacovigilance system versus national spontaneous reporting for collecting safety data on concerning off-label prescribing practices: an example with baclofen and alcohol dependence in France. Drug Saf. 2016. doi:10.1007/s40264-016-0489-7 [Epub ahead of print].

  3. Baldwin DS, Tiwari N, Gordon R. Sense and sensibility when prescribing ‘off-label’ to psychiatric patients. Curr Pharm Des. 2015;21(23):3276–9.

    Article  CAS  PubMed  Google Scholar 

  4. Montori VM, Brito JP, Murad MH. The optimal practice of evidence-based medicine: incorporating patient preferences in practice guidelines. JAMA. 2013;310(23):2503–4.

    Article  CAS  PubMed  Google Scholar 

  5. Rolland B, Deheul S, Danel T, et al. A system of prescriptions without drug approval: example of baclofen. Therapie. 2010;65(6):511–8.

    Article  PubMed  Google Scholar 

  6. Rolland B, Bordet R, Cottencin O. Alcohol-dependence: the current French craze for baclofen. Addiction. 2012;107(4):848–9.

    Article  PubMed  Google Scholar 

  7. Simioni N, Preda C, Deken V, et al. Characteristics of patients with alcohol dependence seeking baclofen treatment in France: a two-centre comparative cohort study. Alcohol Alcohol. 2016;51(6):664–9.

    Article  PubMed  Google Scholar 

  8. Rolland B, Labreuche J, Duhamel A, et al. Baclofen for alcohol dependence: relationships between baclofen and alcohol dosing and the occurrence of major sedation. Eur Neuropsychopharmacol. 2015;25(10):1631–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre Régional de Pharmacovigilance, CHU Lille, Lille Cedex, France

    Marine Auffret, Régis Bordet & Sophie Gautier

  2. Université de Lille, CHU Lille, EA 2694-Santé Publique: épidémiologie et qualité des soins, Lille Cedex, France

    Julien Labreuche & Alain Duhamel

  3. Service d’Addictovigilance, CHU Lille, Lille Cedex, France

    Sylvie Deheul & Régis Bordet

  4. Service d’Addictologie, CHU Lille, Lille Cedex, France

    Olivier Cottencin & Benjamin Rolland

  5. ScaLAB UMR 9193, Université de Lille, Lille Cedex, France

    Olivier Cottencin

  6. INSERM U1171, Département de Pharmacologie Médicale, Université de Lille, 1 place de Verdun, Lille Cedex, 59045, France

    Régis Bordet, Sophie Gautier & Benjamin Rolland

Authors
  1. Marine Auffret
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Julien Labreuche
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alain Duhamel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sylvie Deheul
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Olivier Cottencin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Régis Bordet
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sophie Gautier
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Benjamin Rolland
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Benjamin Rolland.

Ethics declarations

Funding

No sources of funding were used to assist in the preparation of this letter.

Conflict of interest

Benjamin Rolland was the main investigator of a study on baclofen funded by Ethypharm, and he received fees for lectures or consultancy from Lundbeck, Indivior, AstraZeneca, Bristol-Myers-Squibb, Servier, and Ethypharm. Regis Bordet has received fees for lectures or consultancy from Lundbeck, Otsuka, and Novartis. Olivier Cottencin was an associate investigator in a clinical trial funded by Ethypharm. He has received sponsorship to attend scientific meetings from Lundbeck, BMS, Otsuka, Janssen Cilag, Reckitt Benckiser, Pfizer, and Bouchara Recordati. Sylvie Deheul worked as an independent expert for Ethypharm (independent monitoring committee of a phase I trial). Marine Auffret, Julien Labreuche, Alain Duhamel and Sophie Gautier declare no conflicts of interest related to this letter.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Auffret, M., Labreuche, J., Duhamel, A. et al. Authors’ Reply to Alain Braillon’s Comment on “Proactive regional pharmacovigilance system versus national spontaneous reporting for collecting safety data on concerning off-label prescribing practices: An example with baclofen and alcohol dependence in France’’. Drug Saf 40, 361–362 (2017). https://doi.org/10.1007/s40264-017-0513-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40264-017-0513-6

Keywords

Search

Navigation